I just pulled up the Zacks summary from Yahoo at
quote.yahoo.com
who shows three 3 (hold) ratings. I don't have access to the full Zacks, but this is supposed to be a summary. Personally I don't care what the analysts say. They were recommending IDXX effusively before Monday's 60% loss of market cap.
Thompson's Research:
shows a higher 2.3 rating on the 1 Buy - 5 Sell scale
no insider sales since early 95
Top 5 Institutions own 31.8% as of late 96
Top 5 Funds own 13.3% as of late 96
and Top 5 insiders own 10%
They do have a fairly healthy short interest, but shorts aren't always right, but certainly like to try to push things in their favor. I'd like to see the Zacks 5 rating source.
Pull up Recap for more info and follow company link to Collagen
recap.com
They show book value at $11.25, from most recent quarter, but TGET has gone up more than 50% from then, and this isn't reflected in the book value. I'd guess it to be at least $5 higher.
I like the cash pile, the 1.3 M shares of TGET at $68+ soon to be BSX worth $90M or so and the profits, yield and low PE. Plus they have new products in the pipeline, the afforementioned Lipomatrix "vege-boob", and they are always incubating startups. This is so low risk compared to most biotech/meds, maybe it just doesn't have the glamour of the maybe blockbuster billion dollar drug companies if and when they get through clinical to keep the analysts properly starry-eyed.
But, hey by all means do your own DD, these are just web source info and my opinions, all sketchy at best...
Dave |
